Clinical Trial Update: DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating durvalumab with chemotherapy as first-line therapy for advanced malignant pleural mesothelioma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• Chemotherapy (platinum-based regimen) (platinum-based chemotherapy)
• Durvalumab (durvalumab)

Snippet

Sponsor: PrECOG, LLC. | Conditions: Mesothelioma, Pleural Mesothelioma | Phase 3 | Status: COMPLETED